Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

LY-402913, a selective MRP1 inhibitor with in vivo resistance-modulating activity

April 30, 2002

Combination of antimetabolite and thymidine phosphorylase inhibitor in clinical development at Taiho

April 30, 2002

Drug used for xerostomia may help prevent lung cancer

April 30, 2002

Lexicon Genetics discovers new oncogene for development of anticancer drugs

April 30, 2002

Marketing application filed in E.U. for Axcan's photodynamic therapy

April 30, 2002

Pharmacyclics claims metallotexaphyrins and use in diagnosis and therapy

April 29, 2002

Faslodex approved in U.S. for tamoxifen-resistant breast cancer

April 29, 2002

EMEA accepts Thalomid MAA for review

April 29, 2002

Potent and selective CDK2 inhibitors with antitumor activity reported at ACS meeting

April 29, 2002

Pharmacia presents new integrin antagonists in patent literature

April 26, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....